Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.30M$1.30Mderived−85.9% vs Q4 2024 Net Income-$19.80M-$19.80MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$22,734,000N/M Operating Cash Flowderived-$13,131,000N/M Free Cash Flowderived-$13,155,000N/M Margins · derivedOperating margin-1755.5%−673.3 pt vs Q4 2024
Net margin-1528.6%−480.2 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end